Stephen R Marder
#106,076
Most Influential Person Now
Researcher ORCID ID = 0000-0003-0288-309X
Stephen R Marder's AcademicInfluence.com Rankings
Stephen R Marderphilosophy Degrees
Philosophy
#4289
World Rank
#6757
Historical Rank
Logic
#1787
World Rank
#2628
Historical Rank
Download Badge
Psychology Philosophy
Why Is Stephen R Marder Influential?
(Suggest an Edit or Addition)Stephen R Marder's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Remission in schizophrenia: proposed criteria and rationale for consensus. (2005) (2004)
- The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. (2008) (1839)
- The NIMH-MATRICS consensus statement on negative symptoms. (2006) (1094)
- Approaching a consensus cognitive battery for clinical trials in schizophrenia: The NIMH-MATRICS conference to select cognitive domains and test criteria (2004) (867)
- Physical health monitoring of patients with schizophrenia. (2004) (829)
- Risperidone in the treatment of schizophrenia. (1994) (828)
- The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. (1997) (668)
- The brief negative symptom scale: psychometric properties. (2011) (606)
- The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization. (2008) (590)
- Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. (2003) (582)
- Novel antipsychotics: comparison of weight gain liabilities. (1999) (577)
- Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials (2003) (452)
- A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. (2005) (436)
- Does risperidone improve verbal working memory in treatment-resistant schizophrenia? (1997) (418)
- Social cognition in schizophrenia: Relationships with neurocognition and negative symptoms (2007) (403)
- Novel antipsychotics and new onset diabetes (1998) (396)
- The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. (2007) (390)
- Measurement and Treatment Research to Improve Cognition in Schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia (2004) (369)
- Mapping genomic loci implicates genes and synaptic biology in schizophrenia (2022) (361)
- The effects of novel antipsychotics on glucose and lipid levels. (2002) (315)
- The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. (2007) (287)
- The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. (2004) (280)
- The current conceptualization of negative symptoms in schizophrenia (2017) (274)
- Alcohol abuse and dependence: psychopathology, medical management and dental implications. (2003) (267)
- Stages of onset of schizophrenic psychosis. (1978) (253)
- Psychopharmacologic treatment of schizophrenia. (1993) (245)
- Psychosocial treatments to promote functional recovery in schizophrenia. (2009) (237)
- Subjective response to antipsychotic drugs. (1981) (235)
- Technique for training schizophrenic patients in illness self-management: a controlled trial. (1992) (231)
- The MCCB impairment profile for schizophrenia outpatients: Results from the MATRICS psychometric and standardization study (2011) (224)
- Low- and conventional-dose maintenance therapy with fluphenazine decanoate. Two-year outcome. (1987) (221)
- MRI evaluation of brain iron in earlier- and later-onset Parkinson's disease and normal subjects. (1999) (221)
- The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone (2002) (210)
- Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial (2017) (209)
- Informed consent: assessment of comprehension. (1998) (208)
- Efficacy and Safety of Paliperidone Extended-Release Tablets: Results of a 6-Week, Randomized, Placebo-Controlled Study (2007) (203)
- Two-year outcome of social skills training and group psychotherapy for outpatients with schizophrenia. (1996) (203)
- Functional co-primary measures for clinical trials in schizophrenia: results from the MATRICS Psychometric and Standardization Study. (2008) (202)
- Long-Acting Injectable Risperidone for Relapse Prevention and Control of Breakthrough Symptoms After a Recent First Episode of Schizophrenia. A Randomized Clinical Trial. (2015) (199)
- Pharmacokinetics and tissue distribution of olanzapine in rats (1999) (193)
- Treatment of schizophrenia negative symptoms: future prospects. (2006) (191)
- A controlled dose comparison of haloperidol in newly admitted schizophrenic patients. (1990) (187)
- MR evaluation of age-related increase of brain iron in young adult and older normal males. (1997) (181)
- Clozapine and haloperidol in moderately refractory schizophrenia: a 6-month randomized and double-blind comparison. (2001) (177)
- Ultra-rare genetic variation in the epilepsies: a whole-exome sequencing study of 17,606 individuals (2019) (176)
- Initiatives to promote the discovery of drugs to improve cognitive function in severe mental illness. (2006) (171)
- KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia. (2017) (171)
- Field dependent transverse relaxation rate increase may be a specific measure of tissue iron stores (1993) (168)
- Behavioral toxicity of antipsychotic drugs. (1987) (165)
- Costs and benefits of two doses of fluphenazine. (1984) (164)
- Sex, Race, and Smoking Impact Olanzapine Exposure (2008) (161)
- A comparison of patients who refuse and consent to neuroleptic treatment. (1983) (159)
- Efficacy and specificity of social cognitive skills training for outpatients with psychotic disorders. (2011) (157)
- Haloperidol plasma levels and clinical response: a therapeutic window relationship. (1992) (155)
- A Randomized Clinical Trial of MK-0777 for the Treatment of Cognitive Impairments in People with Schizophrenia (2011) (154)
- Rare coding variants in ten genes confer substantial risk for schizophrenia (2022) (154)
- Treatment with atypical antipsychotics: new indications and new populations. (2001) (148)
- Akathisia with haloperidol and thiothixene. (1984) (147)
- Schizophrenia--time to commit to policy change. (2014) (146)
- In vivo MR evaluation of age-related increases in brain iron. (1994) (145)
- In vivo evaluation of brain iron in Alzheimer's disease and normal subjects using MRI (1994) (140)
- Evidence for genetic heterogeneity between clinical subtypes of bipolar disorder (2017) (136)
- Evaluation of functionally meaningful measures for clinical trials of cognition enhancement in schizophrenia. (2011) (134)
- Neuroleptic plasma levels. (1991) (133)
- Clinical Trials of Potential Cognitive-Enhancing Drugs in Schizophrenia: What Have We Learned So Far? (2011) (133)
- Prefrontal–posterior parietal networks in schizophrenia: primary dysfunctions and secondary compensations (2003) (133)
- Facilitating compliance with antipsychotic medication. (1998) (130)
- The Mount Sinai conference on the pharmacotherapy of schizophrenia. (2002) (129)
- Reliability of in vivo volume measures of hippocampus and other brain structures using MRI. (1993) (125)
- The FDA-NIMH-MATRICS guidelines for clinical trial design of cognitive-enhancing drugs: what do we know 5 years later? (2011) (124)
- The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future research (2020) (121)
- A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. (2009) (121)
- Oxytocin-Augmented Social Cognitive Skills Training in Schizophrenia (2014) (119)
- Dopamine-beta-hydroxylase activity and homovanillic acid in spinal fluid of schizophrenics with brain atrophy. (1983) (118)
- Dose response of prophylactic antipsychotics. (1993) (117)
- Overview of partial compliance. (2003) (115)
- Effort-Based Decision-Making Paradigms for Clinical Trials in Schizophrenia: Part 1—Psychometric Characteristics of 5 Paradigms. (2015) (114)
- Right lateral fusiform gyrus dysfunction during facial information processing in schizophrenia (2003) (112)
- Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia (2012) (111)
- Clinical Guidance on the Identification and Management of Treatment-Resistant Schizophrenia. (2019) (111)
- Effects of single dose intranasal oxytocin on social cognition in schizophrenia (2013) (110)
- Schizophrenic patients' perceptions of their relatives' attitudes (1995) (109)
- Response to antipsychotic medication: the doctor's and the consumer's view. (1984) (107)
- The White Tiger. (2009) (106)
- d-Amphetamine-induced heterogeneous changes in psychotic behavior in schizophrenia. (1982) (104)
- Eye movements in schizophrenia. (1987) (104)
- Social Cognition and Neurocognition: Effects of Risperidone, Olanzapine, and Haloperidol. (2007) (102)
- Risperidone nonadherence and return of positive symptoms in the early course of schizophrenia. (2011) (101)
- The psychopathology, medical management and dental implications of schizophrenia. (2002) (100)
- Supplementing clinic-based skills training with manual-based community support sessions: effects on social adjustment of patients with schizophrenia. (2002) (99)
- Risperidone versus haloperidol on secondary memory: can newer medications aid learning? (1999) (98)
- Risperidone in treatment-refractory schizophrenia. (1999) (91)
- Report from the working group conference on multisite trial design for cognitive remediation in schizophrenia. (2011) (90)
- A review of agitation in mental illness: treatment guidelines and current therapies. (2006) (89)
- Pharmacological approaches to treating negative symptoms: A review of clinical trials (2013) (89)
- Maintenance treatment of schizophrenia with risperidone or haloperidol: 2-year outcomes. (2003) (89)
- Effort-Based Decision-Making Paradigms for Clinical Trials in Schizophrenia: Part 2—External Validity and Correlates. (2015) (89)
- Risperidone vs. haloperidol on reaction time, manual dexterity, and motor learning in treatment-resistant schizophrenia patients (1998) (89)
- Association of prominent positive and prominent negative symptoms and functional health, well-being, healthcare-related quality of life and family burden: A CATIE analysis (2013) (88)
- Sexual side effects of novel antipsychotic medications (2002) (86)
- Plasma level monitoring of olanzapine in patients with schizophrenia: determination by high-performance liquid chromatography with electrochemical detection. (1997) (86)
- A brief cognitive assessment tool for schizophrenia: construction of a tool for clinicians. (2011) (84)
- Fluoxetine, akathisia, and suicidality: is there a causal connection? (1992) (83)
- Bitopertin in Negative Symptoms of Schizophrenia—Results From the Phase III FlashLyte and DayLyte Studies (2017) (83)
- Characteristics and use patterns of patients taking first-generation depot antipsychotics or oral antipsychotics for schizophrenia. (2007) (82)
- Who should receive clozapine? (1988) (81)
- Span of Apprehension Performance, Neuropsychological Functioning, and Indices of Psychosis‐Proneness (1983) (80)
- Do clozapine and risperidone affect social competence and problem solving? (2004) (80)
- A randomized, double-blind, placebo-controlled trial of modafinil for negative symptoms in schizophrenia. (2007) (79)
- Effects of olanzapine, risperidone and haloperidol on prepulse inhibition in schizophrenia patients: A double-blind, randomized controlled trial (2007) (79)
- Apathy in first episode psychosis patients: One year follow up (2010) (77)
- Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study. (2008) (76)
- Fluphenazine vs placebo supplementation for prodromal signs of relapse in schizophrenia. (1994) (74)
- The effect of pimozide on CSF norepinephrine in schizophrenia. (1981) (74)
- Phase 2 Trial of an Alpha-7 Nicotinic Receptor Agonist (TC-5619) in Negative and Cognitive Symptoms of Schizophrenia. (2016) (73)
- Management of acute extrapyramidal effects induced by antipsychotic drugs. (1997) (72)
- Evidence-based pharmacologic treatment for people with severe mental illness: a focus on guidelines and algorithms. (2001) (72)
- Methodological issues in negative symptom trials. (2011) (71)
- The NIMH-MATRICS project for developing cognition-enhancing agents for schizophrenia (2006) (71)
- Adapting social neuroscience measures for schizophrenia clinical trials, Part 2: trolling the depths of psychometric properties. (2013) (71)
- Selective corticostriatal dysfunction in schizophrenia: examination of motor and cognitive skill learning. (2008) (70)
- The heterogeneity of schizophrenia in disease states (2004) (70)
- Plasma concentrations of risperidone and its 9-hydroxy metabolite and their relationship to dose in schizophrenic patients: simultaneous determination by a high performance liquid chromatography with electrochemical detection. (1998) (69)
- Distribution after repeated oral administration of different dose levels of risperidone and 9-hydroxy-risperidone in the brain and other tissues of rat (1998) (69)
- A multidose study of haloperidol decanoate in the maintenance treatment of schizophrenia. (2002) (68)
- Time to discontinuation of depot and oral first-generation antipsychotics in the usual care of schizophrenia. (2008) (68)
- Contributions of common genetic variants to risk of schizophrenia among individuals of African and Latino ancestry (2019) (65)
- Dual-task performance operating characteristics, resource limitations, and automatic processing in schizophrenia. (1996) (65)
- Clinical predictors of response to clozapine treatment in ambulatory patients with schizophrenia. (2002) (63)
- Psychotic patients' understanding of informed consent. (1985) (63)
- In Vivo Amplified Skills Training: Promoting Generalization of Independent Living Skills for Clients with Schizophrenia (2002) (62)
- Risperidone, 2 mg/day vs. 4 mg/day, in first-episode, acutely psychotic patients: treatment efficacy and effects on fine motor functioning. (2002) (62)
- Patients' Perceptions of Family Emotional Climate and Outcome in Schizophrenia (1993) (62)
- Antipsychotic and anticholinergic effects on two types of spatial memory in schizophrenia (2004) (61)
- The genomic psychiatry cohort: Partners in discovery (2013) (61)
- Defining and measuring negative symptoms of schizophrenia in clinical trials (2014) (60)
- The effects of clozapine and risperidone on spatial working memory in schizophrenia. (2005) (59)
- Effects of Davunetide on N-acetylaspartate and Choline in Dorsolateral Prefrontal Cortex in Patients with Schizophrenia (2013) (59)
- An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels. (2021) (58)
- Psychopharmacology of the negative symptoms: Current status and prospects for progress (2014) (57)
- Simultaneous determination of risperidone and 9-hydroxyrisperidone in plasma by liquid chromatography/electrospray tandem mass spectrometry. (2000) (56)
- Social cognition [corrected] and neurocognition: effects of risperidone, olanzapine, and haloperidol. (2007) (56)
- A Phase II study of a histamine H3 receptor antagonist GSK239512 for cognitive impairment in stable schizophrenia subjects on antipsychotic therapy (2015) (56)
- Apathy, poor verbal memory and male gender predict lower psychosocial functioning one year after the first treatment of psychosis (2013) (56)
- Social skills and relapse history in outpatient schizophrenics. (1990) (55)
- Preliminary associations between motor procedural learning, basal ganglia T2 relaxation times, and tardive dyskinesia in schizophrenia (1993) (54)
- Simultaneous determination of clozapine and its N-desmethyl and N-oxide metabolites in plasma by liquid chromatography/electrospray tandem mass spectrometry and its application to plasma level monitoring in schizophrenic patients. (2001) (54)
- The acute efficacy of aripiprazole across the symptom spectrum of schizophrenia: a pooled post hoc analysis from 5 short-term studies. (2009) (53)
- Plasma levels of haloperidol and clinical response. (1985) (53)
- Drug treatment of schizophrenia Overview of recent research (1991) (53)
- Schizophrenia, IX: Cognition in schizophrenia--the MATRICS initiative. (2004) (53)
- A Compensatory Mirror Cortical Mechanism for Facial Affect Processing in Schizophrenia (2001) (50)
- MRI in tardive dyskinesia: Shortened left caudate T2 (1990) (50)
- Bipolar I disorder: psychopathology, medical management and dental implications. (2002) (49)
- Case reports of postmarketing adverse event experiences with olanzapine intramuscular treatment in patients with agitation. (2010) (48)
- Chronic restlessness with antipsychotics. (2007) (48)
- Brain, plasma and tissue pharmacokinetics of risperidone and 9-hydroxyrisperidone after separate oral administration to rats (2002) (48)
- Controlled information processing resources and the development of automatic detection responses in schizophrenia. (1991) (46)
- Determination of risperidone in plasma by high-performance liquid chromatography with electrochemical detection: application to therapeutic drug monitoring in schizophrenic patients. (1993) (46)
- A study of medication refusal by involuntary psychiatric patients. (1984) (45)
- Issues and perspectives in designing clinical trials for negative symptoms in schizophrenia (2013) (45)
- Plasma Levels of Fluphenazine in Patients Receiving Fluphenazine Decanoate Relationship to Clinical Response (1991) (44)
- Tardive Meige syndrome responsive to clozapine. (1990) (43)
- Mid-term and long-term efficacy and effectiveness of antipsychotic medications for schizophrenia: a data-driven, personalized clinical approach. (2011) (43)
- Anticholinergic Effects on Memory: Benztropine versus Amantadine (1989) (43)
- Early prediction of relapse in schizophrenia: an application of receiver operating characteristic (ROC) methods. (1991) (42)
- CSF Dopamine β-Hydroxylase in Schizophrenia: Low Activity Associated With Good Prognosis and Good Response to Neuroleptic Treatment (1983) (41)
- Improving measurement of attributional style in schizophrenia; A psychometric evaluation of the Ambiguous Intentions Hostility Questionnaire (AIHQ). (2017) (41)
- Guidelines for Neuroleptic Relapse Prevention in Schizophrenia: Towards a Consensus View (1991) (41)
- Blood Levels to Optimize Antipsychotic Treatment in Clinical Practice: A Joint Consensus Statement of the American Society of Clinical Psychopharmacology and the Therapeutic Drug Monitoring Task Force of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie. (2020) (41)
- Predicting drug-free improvement in schizophrenic psychosis. (1979) (41)
- Information processing and neuroleptic response in acute and stabilized schizophrenic patients (1984) (41)
- Antipsychotic effects of pimozide in schizophrenia. Treatment response prediction with acute dextroamphetamine response. (1982) (40)
- Anterior cingulate dysfunction during choice anticipation in schizophrenia (2004) (40)
- Optimal drug and behavior therapy for treatment-refractory schizophrenic patients. (1994) (40)
- Drug initiatives to improve cognitive function. (2006) (39)
- Report on ISCTM Consensus Meeting on Clinical Assessment of Response to Treatment of Cognitive Impairment in Schizophrenia (2015) (39)
- Characteristics and Use Patterns of Patients Taking First-Generation Depot Antipsychotics or Oral Antipsychotics for Schizophrenia (2007) (38)
- Psychotherapy and pharmacotherapy: conceptual lenses. (1977) (38)
- RISPERIDONE: CLINICAL DEVELOPMENT: NORTH AMERICAN RESULTS (1992) (36)
- Contribution of Rare Copy Number Variants to Bipolar Disorder Risk Is Limited to Schizoaffective Cases (2018) (36)
- Adapting social neuroscience measures for schizophrenia clinical trials, part 3: fathoming external validity. (2013) (36)
- Serum prolactin as a correlate of clinical response to haloperidol. (1991) (35)
- Antipsychotic drugs and relapse prevention (1999) (35)
- Differential effect of low and conventional doses of fluphenazine on schizophrenic outpatients with good or poor information-processing abilities. (1988) (35)
- Intra- and Interindividual Variations in Steady-State Plasma Concentrations of Risperidone and 9-Hydroxyrisperidone in Schizophrenic Patients Treated Chronically with Various Doses of Risperidone (2003) (34)
- The Effects of Risperidone vs Haloperidol on Cognitive Functioning in Treatment-Resistant Schizophrenia: The Trail Making Test (1997) (34)
- Clozapine for substance-abusing schizophrenic patients. (1999) (33)
- Definitions of the Term ‘Recovered’ in Schizophrenia and Other Disorders (2008) (33)
- Aripiprazole effects in patients with acute schizophrenia experiencing higher or lower agitation: a post hoc analysis of 4 randomized, placebo-controlled clinical trials. (2007) (32)
- The expert consensus guideline series (2009) (32)
- Efficacy of cariprazine across symptom domains in patients with acute exacerbation of schizophrenia: Pooled analyses from 3 phase II/III studies (2019) (32)
- Distribution of Fluphenazine and Its Metabolites in Brain Regions and Other Tissues of the Rat (1995) (32)
- Rehab rounds: Training in social problem solving among persons with schizophrenia. (2001) (32)
- Posttraumatic stress disorder: psychopathology, medical management, and dental implications. (2004) (32)
- Population Pharmacokinetics of Perphenazine in Schizophrenia Patients From CATIE: Impact of Race and Smoking (2010) (31)
- Dialysis for schizophrenia: review of clinical trials and implications for further research. (1980) (31)
- Efficacy of lurasidone across five symptom dimensions of schizophrenia: Pooled analysis of short-term, placebo-controlled studies (2015) (30)
- Can risperidone reduce cocaine use in substance abusing schizophrenic patients? (2002) (28)
- Schizophrenia: Comprehensive Treatment and Management (2002) (28)
- Supplementing Clinic-Based Skills Training With Manual-Based Community Support Sessions: Effects on Social Adjustment of Patients With Schizophrenia (2004) (28)
- Management of treatment-resistant patients with schizophrenia. (1996) (28)
- Display visual angle and attentional scanpaths on the span of apprehension task in schizophrenia. (1996) (27)
- The Neurobiology of Treatment-Resistant Schizophrenia: Paths to Antipsychotic Resistance and A Roadmap for Future Research. (2020) (27)
- Olanzapine treatment for patients with schizophrenia and cocaine abuse. (2002) (27)
- Tardive dyskinesia and serum iron indices (1998) (27)
- Understanding the Association Between Negative Symptoms and Performance on Effort-Based Decision-Making Tasks: The Importance of Defeatist Performance Beliefs (2018) (27)
- Efficacy and safety of the glycine transporter type-1 inhibitor AMG 747 for the treatment of negative symptoms associated with schizophrenia (2017) (27)
- Routine Outcomes Monitoring to Support Improving Care for Schizophrenia: Report from the VA Mental Health QUERI (2010) (26)
- The cultural adaptability of intermediate measures of functional outcome in schizophrenia. (2012) (26)
- The prediction of relapse of schizophrenic patients using emotional data obtained from their relatives (1988) (26)
- Long-term pimozide pretreatment differentially affects behavioral responses to dextroamphetamine in schizophrenia. Further exploration of the dopamine hypothesis of schizophrenia. (1982) (26)
- Lithium attenuates the activation-euphoria but not the psychosis induced by d-amphetamine in schizophrenia (2004) (25)
- Time to rehospitalization of clozapine versus risperidone in the naturalistic treatment of comorbid alcohol use disorder and schizophrenia (2008) (25)
- History of Psychopharmacology. (2019) (25)
- Simultaneous determination of plasma haloperidol and its metabolite reduced haloperidol by liquid chromatography with electrochemical detection. Plasma levels in schizophrenic patients treated with oral or intramuscular depot haloperidol. (1994) (25)
- Reliability, validity and ability to detect change of the PANSS negative symptom factor score in outpatients with schizophrenia on select antipsychotics and with prominent negative or disorganized thought symptoms (2014) (25)
- MAO activity, csf amine metabolites, and drug-free improvement in schizophrenia. (1978) (25)
- Acquisition and retention of skills training methods in chronic schizophrenic outpatients. (1992) (24)
- Lack of behavioral supersensitivity to d-amphetamine after pimozide withdrawal. A trial with schizophrenic patients. (1980) (24)
- Brexpiprazole in patients with schizophrenia: overview of short- and long-term phase 3 controlled studies (2016) (24)
- Determination of ziprasidone in human plasma by liquid chromatography-electrospray tandem mass spectrometry and its application to plasma level determination in schizophrenia patients. (2007) (24)
- Advancing drug discovery for schizophrenia (2011) (24)
- Better pharmacotherapy for schizophrenia: What does the future hold? (2008) (24)
- New paradigms for treatment development. (2007) (23)
- Effects of clozapine on treatment-resistant akathisia and concomitant tardive dyskinesia. (1990) (23)
- The effects of curcumin on brain-derived neurotrophic factor and cognition in schizophrenia: A randomized controlled study (2017) (23)
- Clinical guidelines: Dosing and switching strategies for long-acting risperidone. (2003) (23)
- Fluphenazine plasma level monitoring for patients receiving fluphenazine decanoate (2002) (23)
- Depot neuroleptics: side effects and safety. (1986) (22)
- The reliability and validity of the MATRICS functional assessment battery. (2014) (22)
- Population Pharmacokinetic Modeling of Ziprasidone in Patients With Schizophrenia From the CATIE Study (2011) (22)
- Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia. (1994) (22)
- A dose-finding study of oxytocin using neurophysiological measures of social processing (2018) (22)
- Proof of mechanism and target engagement of glutamatergic drugs for the treatment of schizophrenia: RCTs of pomaglumetad and TS-134 on ketamine-induced psychotic symptoms and pharmacoBOLD in healthy volunteers (2020) (21)
- Subjective responses to thiothixene and chlorpromzine. (1980) (21)
- Neuroleptic medication and prescription practices with sheltered-care residents: a 12-year perspective. (1992) (21)
- Toward a more reliable diagnosis of akathisia. (1986) (21)
- Long-term maintenance therapy with quetiapine versus haloperidol decanoate in patients with schizophrenia or schizoaffective disorder. (2005) (20)
- Plasma homovanillic acid as a predictor of response to fluphenazine treatment. (1989) (20)
- Management of schizophrenia. (1996) (20)
- Fluphenazine plasma levels and clinical response. (1990) (19)
- Systematic dosage reduction in treatment-resistant schizophrenic patients. (1993) (19)
- Parsing components of auditory predictive coding in schizophrenia using a roving standard mismatch negativity paradigm (2019) (19)
- Unconscious emotional reasoning and the therapeutic misconception (2008) (19)
- Low-Dose Fluvoxamine as an Adjunct to Reduce Olanzapine Therapeutic Dose Requirements: A Prospective Dose-Adjusted Drug Interaction Strategy (2005) (19)
- An RCT Evaluating the Effects of Skills Training and Medication Type on Work Outcomes Among Patients With Schizophrenia. (2017) (19)
- Predictive value of eosinophilia for neutropenia during clozapine treatment. (1996) (18)
- Clinical utility of magnetic resonance imaging radiographs for suspected organic syndromes in adult psychiatry. (2005) (18)
- Acute amphetamine response predicts antidepressant and antipsychotic responses to lithium carbonate in schizophrenic patients (1981) (18)
- d-Amphetamine raises serum prolactin in man: evaluations after chronic placebo, lithium and pimozide treatment. (1978) (18)
- Pharmacokinetics of long-acting injectable neuroleptic drugs: clinical implications (2004) (18)
- Low-dose treatment strategies. (1986) (17)
- How Occupationally High-Achieving Individuals With a Diagnosis of Schizophrenia Manage Their Symptoms. (2017) (17)
- Surreptitious noncompliance with oral fluphenazine in a voluntary inpatient population. (1990) (17)
- Plasma fluphenazine levels and clinical response in newly admitted schizophrenic patients (1991) (16)
- Anticholinergic effects on memory: benztropine vs. amantadine. (1987) (15)
- Evaluating visual neuroplasticity with EEG in schizophrenia outpatients (2019) (15)
- Advancing the treatment of people with mental illness: a call to action in the management of metabolic issues. (2005) (15)
- Application of a single-objective, hybrid genetic algorithm approach to pharmacokinetic model building (2012) (15)
- Limitations of Dopamine-D2 Antagonists and the Search for Novel Antipsychotic Strategies (1999) (15)
- CSF dopamine beta-hydroxylase in schizophrenia. (1983) (15)
- Positron-emission tomography in tardive dyskinesia. (1995) (15)
- Monitoring treatment and managing adherence in schizophrenia. (2013) (15)
- A 10-minute measure of global cognition: Validation of the Brief Cognitive Assessment Tool for Schizophrenia (B-CATS) (2017) (14)
- Newer antipsychotics in treatment-resistant schizophrenia. (1999) (14)
- Schizophrenia: Low spinal fluid GABA levels? (1980) (14)
- A Phase 3, 1-Year, Open-Label Trial of Valbenazine in Adults With Tardive Dyskinesia. (2019) (14)
- Lessons from MATRICS. (2011) (14)
- A one-year comparison of four dosages of haloperidol decanoate (1993) (13)
- Optimizing pharmacotherapy to maximize outcome in schizophrenia. (2005) (13)
- Why Are Innovative Drugs Failing in Phase III? (2017) (13)
- Fluphenazine plasma levels in patients receiving low and conventional doses of fluphenazine decanoate (1986) (13)
- Quality Enhancement Research Initiative in Mental Health. (2000) (13)
- Plasma levels of parent drug and metabolites in patients receiving oral and depot fluphenazine. (1989) (13)
- Efficacy of clozapine versus haloperidol in a long-term clinical trial (1996) (13)
- Alcoholism among male schizophrenic inpatients. (1990) (13)
- Schizophrenia: From Neuroimaging to Neuroscience (2006) (12)
- Age at illness onset and left temporal lobe length in males with schizophrenia (1996) (12)
- Bifactor Modeling of the Positive and Negative Syndrome Scale: Generalized Psychosis Spans Schizoaffective, Bipolar, and Schizophrenia Diagnoses (2018) (12)
- Metabolism of Phenothiazine and Butyrophenone Antipsychotic Drugs (1993) (12)
- Pharmacological treatment strategies in acute schizophrenia (1996) (12)
- Clinical experience with risperidone. (1996) (12)
- Clinician perceptions, expectations, and management of negative symptoms in schizophrenia. (2013) (11)
- Clozapine and risperidone in moderately refractory schizophrenia: a 6-month randomized double-blind comparison. (2016) (11)
- Defining and characterising treatment-resistant schizophrenia (1995) (11)
- Efficacy of clozapine vs haloperidol in a long term clinical trial: Preliminary findings (1995) (11)
- Assessment of Suicidal Ideation and Behavior: Report of the International Society for CNS Clinical Trials and Methodology Consensus Meeting. (2017) (11)
- Persisting negative symptoms and information-processing deficits in schizophrenia: Implications for subtyping (1994) (11)
- Clinical Use of Neuroleptic Plasma Levels (1993) (11)
- The therapeutic index of haloperidol in newly admitted schizophrenic patients. (1987) (11)
- Efficacy and safety of adjunctive bitopertin (10 and 20mg) versus placebo in subjects with persistent predominant negative symptoms of schizophrenia treated with antipsychotics — Results from the Phase III FlashLyte Study (2014) (11)
- Lessons from each drug trial. (2007) (10)
- Clinical trials for negative symptoms — Emerging directions and unresolved issues (2013) (10)
- Can clinical practice guide a research agenda? (2002) (10)
- Reliability and validity of the self-report version of the apathy evaluation scale in first-episode Psychosis: Concordance with the clinical version at baseline and 12 months follow-up (2018) (10)
- The Dysphoria Syndrome and its Relation to EPS (1985) (10)
- Benefits and limitations of neuroleptics--and other forms of treatment--in schizophrenia. (1986) (10)
- 245. The effects of risperidone vs. haloperidol on spatial working memory in treatment-resistant schizophrema (1996) (10)
- T2 hyperintense foci on magnetic resonance images of schizophrenic patients and controls (1991) (10)
- EFFICACY AND SAFETY OF ADJUNCTIVE BITOPERTIN VERSUS PLACEBO IN SUBJECTS WITH PERSISTENT PREDOMINANT NEGATIVE SYMPTOMS OF SCHIZOPHRENIA TREATED WITH ANTIPSYCHOTICS – UPDATE FROM THE SEARCHLYTE PROGRAMME (2014) (9)
- The efficacy of piquindone, a new atypical neuroleptic, in the treatment of the positive and negative symptoms of schizophrenia. (1987) (9)
- Motivational and cognitive correlates of community integration in homeless veterans entering a permanent supported housing program. (2019) (9)
- EFFICACY OF LURASIDONE IN SCHIZOPHRENIA: RESULTS OF A POOLED ANALYSIS BASED ON A 5-FACTOR MODEL OF SCHIZOPHRENIA (2010) (9)
- Perspective: Retreat from the radical (2014) (9)
- Variable dose studies provide misleading therapeutic windows. (1986) (9)
- Cambridge Textbook of Effective Treatments in Psychiatry: Pharmacological treatments for schizophrenia (2008) (9)
- It Is Time to Take a Stand for Medical Research and Against Terrorism Targeting Medical Scientists (2008) (9)
- The neuroleptic malignant syndrome manifested as a prolonged confusional state. (1988) (9)
- Association of 9-Hydroxy Risperidone Concentrations With Risk of Switching or Discontinuation in the Clinical Antipsychotic Trial of Intervention Effectiveness-Alzheimer's Disease Trial (2010) (8)
- Medical Illness and Schizophrenia, 2nd ed (2010) (8)
- Post hoc analysis of a randomised, placebo-controlled, active-reference 6-week study of brexpiprazole in acute schizophrenia (2020) (8)
- Panic disorder: psychopathology, medical management and dental implications. (2004) (8)
- Adjunctive fluoxetine in haloperidol-stabilized schizophrenics (1993) (8)
- Task-related fMRI responses to a nicotinic acetylcholine receptor partial agonist in schizophrenia: A randomized trial (2016) (7)
- “Will I need to take these medications for the rest of my life?” (2018) (7)
- An approach to treatment resistance in schizophrenia (1999) (7)
- "Selective corticostriatal dysfunction in schizophrenia: Examination of motor and cognitive skill learning": Correction to Foerde et al. (2008). (2008) (7)
- Switch or Stay (2006) (7)
- P.2.108 Plasma lipids levels and glycemic control in long-term treatment with aripiprazole (2003) (7)
- Radioimmunoassay and other methods for trace analysis of N-oxide compounds (1991) (7)
- MAINTENANCE THERAPY OF SCHIZOPHRENIA (1983) (7)
- Neurocognition as a Treatment Target in Schizophrenia (2008) (7)
- l-5-Hydroxytryptophan-induced delirium (1986) (7)
- SPINAL FLUID GABA LEVELS IN SCHIZOPHRENIA (1981) (6)
- Management of risk of relapse in schizophrenia (1992) (6)
- Clinical Perspectives of Some Neuroleptics Through Development and Application of Their Assays (1993) (6)
- KINECT 3: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Valbenazine (NBI-98854) for Tardive Dyskinesia (PL02.003) (2016) (6)
- Haloperidol plasma levels and clinical response: a therapeutic window relationship. (1988) (6)
- The impact of clozapine on psychosocial competence (1995) (6)
- Older Brains are Different: Brain-Behavior Studies and Their Clinical Utility. (2017) (6)
- Motivational and cognitive factors linked to community integration in homeless veterans: study 1 – individuals with psychotic disorders (2020) (6)
- L-5-hydroxytryptophan attenuates positive psychotic symptoms induced by D-amphetamine (1987) (6)
- The NIMH MATRICS Initiative: Development of a Consensus Cognitive Battery (2007) (6)
- Magnetic resonance imaging evaluation of brain iron levels (1995) (6)
- Plasma haloperidol levels: clinical response and fancy mathematics. (1985) (6)
- 546 Risperidone vs. Haloperidol in treatment resistant schizophrenia (1997) (6)
- 65-77 The clinical actions of risperidone (1997) (6)
- Plasma level monitoring for maintenance neuroleptic therapy. (1989) (6)
- Conclusions and treatment recommendations for the acute episode in schizophrenia (1996) (6)
- Restrictive symptomatic inclusion criteria create barriers to clinical research in schizophrenia negative symptoms: An analysis of the CATIE dataset (2014) (6)
- P.3.d.036 Efficacy of cariprazine on predominant negative symptoms of patients with schizophrenia: post hoc analysis of PANSS data, Marder factors, and cognition (2016) (6)
- Psychosocial and pharmacological strategies for maintenance therapy: Effects on two-year outcome (1993) (5)
- Issues and Perspectives in Designing Clinical Trials for Negative Symptoms in Schizophrenia: Consensus Statements (2020) (5)
- Information processing and maintenance dose requirements in schizophrenia. (1988) (5)
- Risperidone vs. haloperidol in treatment resistant schizophrenia: Preliminary results (1996) (5)
- Reducing rehospitalization rates for patients with schizophrenia: The community re-entry supplemental intervention (2003) (5)
- Brain glutathione levels and age at onset of illness in chronic schizophrenia (2019) (5)
- Circulating prolacatin predicts risk of exacerbation in patients on depot fluphenazine (1987) (5)
- MK-0777 FOR THE TREATMENT OF COGNITIVE IMPAIRMENTS IN PEOPLE WITH SCHIZOPHRENIA (2010) (5)
- Radioimmunoassay for 7‐Hydroxy Metabolite of Fluphenazine and its Application to Plasma Level Monitoring in Schizophrenic Patients Treated Long Term with Oral and Depot Fluphenazine (1994) (5)
- Pharmacologic Treatment of Veterans With Posttraumatic Stress Disorder and Concomitant Affective Disorder (1989) (5)
- Plasma fluphenazine levels in patients receiving two doses of fluphenazine decanoate. (1986) (5)
- Cambridge Textbook of Effective Treatments in Psychiatry: Psychosocial and pharmacological treatments for schizophrenia (2008) (5)
- Clinical instruments to evaluate and guide treatment in schizophrenia. (2012) (4)
- Alpha-7 nicotinic agonist improves cognition in schizophrenia (2016) (4)
- Clinical Efficacy and Target Engagement of Glutamatergic Drugs: Placebo-Controlled RCTs of Pomaglumetad and TS-134 for Reversal of Ketamine-Induced Psychotic Symptoms and PharmacoBOLD in Healthy Volunteers (2020) (4)
- Atypical antipsychotic agents in the treatment of schizophrenia and other psychiatric disorders. Part I: Unique patient populations. (1998) (4)
- The effects of clozapine and haldol on memory functioning in treatment refractory schizophrenics (1996) (4)
- Risperidone versus olanzapine among patients with schizophrenia participating in supported employment: Eighteen-month outcomes. (2017) (4)
- Pharmacological treatment of schizophrenia (1992) (4)
- Therapeutic Monitoring of Steady‐State Plasma Levels of the N4'‐Oxide Metabolite of Fluphenazine in Chronically Treated Schizophrenic Patients Determined by a Specific and Sensitive Radioimmunoassay (1990) (4)
- N-acetylcysteine improves EEG measures of auditory deviance detection and neural synchronization in schizophrenia: A randomized, controlled pilot study (2019) (4)
- Disparity between General Symptom Relief and Remission Criteria in the Positive and Negative Syndrome Scale (PANSS): A Post-treatment Bifactor Item Response Theory Model. (2017) (4)
- Brief Negative Symptom Scale (2014) (4)
- Motivational and cognitive factors linked to community integration in homeless veterans: Study 2 – clinically diverse sample (2020) (4)
- A supplementary Russian-English dictionary (1992) (4)
- Schizophrenia: Recent advances in diagnosis and treatment (2014) (4)
- Assessment of negative symptoms in clinical trials of acute schizophrenia (2022) (3)
- Switch or stay? (2006) (3)
- Relatives' expressed emotion (EE) vs. patients' perceptions of EE: Which is a better predictor of course? (1993) (3)
- A Candidate Pathway Strategy for Integration of Pharmacogenomic Components of Variability in Antipsychotic Treatment Outcomes: A Focus on Aripiprazole (2005) (3)
- The determination of the steady-state pharmacokinetic profile of fluphenazine decanoate by gas chromatography/mass spectrometry detection (1992) (3)
- Atrial flutter/fibrillation associated with tranylcypromine treatment. (1981) (3)
- Natural Language Processing: Its Potential Role in Clinical Care and Clinical Research. (2022) (3)
- Treatment of agitation in patients with schizophrenia. (2008) (3)
- Prediction of schizophrenic relapse using prodromal symptoms (1993) (3)
- Plasma level monitoring of depot neuroleptics (1991) (3)
- The sulfoxidation of fluphenazine in schizophrenic patients maintained on fluphenazine decanoate (2004) (3)
- Antipsychotic discontinuation and recovery: chicken or egg? (2021) (3)
- Response to Fuchs (1994) (3)
- 530 First improvement with clozapine: How patient should we be? (1997) (3)
- Approaches to Maintenance Therapy in Schizophrenia (1983) (3)
- 605 Risperidone's effects on verbal working memory (1997) (3)
- First and second generation antipsychotics: translating the results from pragmatic trials into clinical practice (2013) (2)
- Rethinking the risks and benefits of long-term maintenance in schizophrenia (2019) (2)
- Variable dose studies provide misleading therapeutic windows. (1986) (2)
- Novel approaches for treating schizophrenia (2012) (2)
- The characteristics of cognitive neuroscience tests in a schizophrenia cognition clinical trial: Psychometric properties and correlations with standard measures (2019) (2)
- Chapter 22 Medication treatment for anxiety, depression, schizophrenia, and bipolar disorder in the community setting (2011) (2)
- 764 Clozapine vs. haloperidol: Drug intolerance in a controlled six month trial (1997) (2)
- Newer Antipsychotics and the Differences Between Clinical Experiences and Clinical Trials (2007) (2)
- 607 Risperidone vs. haloperidol on reaction time and fine motor speed (1997) (2)
- Constance E. Lieber, Theodore R. Stanley, and the Enduring Impact of Philanthropy on Psychiatry Research (2016) (2)
- Learning from people with schizophrenia. (2014) (2)
- A long-term, open-label study of valbenazine for tardive dyskinesia (2020) (2)
- Clozapine associated eosinophilia and neutropenia (1995) (2)
- Effects of Brexpiprazole Across Symptom Domains in Patients With Schizophrenia: Post Hoc Analysis of Short- and Long-Term Studies (2021) (2)
- Tolerability of clozapine and risperidone during a twenty nine week trial (2003) (2)
- Using Atypical Antipsychotics in Primary Care. (2002) (2)
- The Missing Link Between Science and Service (2003) (2)
- Effects on clinical psychopathology and fine motor functions of 2 versus 4 MG risperidone in first-episode psychotic patients (2000) (2)
- Hemodialysis in schizophrenia: clinical issues. (1979) (2)
- Efficacy of clozapine vs. haloperidol in a long-term clinical trial: Preliminary results (1995) (2)
- Research Methods in Psychiatry, 3rd ed (2009) (2)
- United States: Neuroleptic Relapse Prevention (1991) (2)
- The hospital and optimal chemotherapy in schizophrenia. (1979) (2)
- P534. Initial Assessment of the Clinical Profile of the PDE10A Inhibitor MK-8189 in Patients With an Acute Episode of Schizophrenia (2022) (1)
- Chapter 25. Maintenance Treatment (2007) (1)
- Patient-family contact may improve outcomes of behaviorally-based rehabilitation programs (2003) (1)
- OXYTOCIN AND SOCIAL COGNITION TRAINING (2014) (1)
- 123 Long-Term Outcomes with Valbenazine 40 mg/day in Adults With Tardive Dyskinesia (2020) (1)
- PANSS Individual Item and Marder Dimension Analyses From a Pivotal Trial of RBP-7000 (Monthly Extended-Release Risperidone) in Schizophrenia Patients. (2021) (1)
- Financial exploitation of schizophrenic patients by their families. (1982) (1)
- Poster #199 CLINICAL TRIALS OF POTENTIAL COGNITIVE-ENHANCING DRUGS IN SCHIZOPHRENIA: WHAT HAVE WE LEARNED SO FAR? (2012) (1)
- Atypical antipsychotic agents in the treatment of Schizophrenia and other psychiatric disorders. Part II: Special considerations. (1998) (1)
- 6. Pharmacological Treatment (2011) (1)
- SCHIZOPHRENIA 12 . 8 SCHIZOPHRENIA : SOMATIC TREATMENT (2004) (1)
- Response to Gordon and Green Letter (2011) (1)
- Helping persons with schizophrenia stay employed: Challenges to implementing the workplace fundamentals module in the clinic (2003) (1)
- APA PRACTICE GUIDELINE FOR SCHIZOPHRENIA : RISPERIDONE EQUIVALENTS. AUTHORS' REPLY (1998) (1)
- Principles of Pharmacological Treatment in Schizophrenia (2011) (1)
- Determination of plasma homovanillic acid by column liquid chromatography with electrochemical detection. (1990) (1)
- A Cruel Irony for Clinicians Who Treat Depression. (2017) (1)
- Effects of Long-Term Valbenazine on Tardive Dyskinesia and Patient-Reported Outcomes: Results from the KINECT 4 Study (P4.078) (2018) (1)
- Commentary on "TM and our models of informed consent" by Charles W. Lidz. (2006) (1)
- Selegiline in the treatment of akathisia, tardive dyskinesia, and negative schizophrenic symptoms (1992) (1)
- Clozapine and risperidone in moderately refractory schizophrenia: A six month double-blind comparison (2003) (1)
- Risperidone vs. haloperidol: Relative liabilities for OCD and depression (1996) (1)
- Sequential Multiple-Assignment Randomized Trials to Compare Antipsychotic Treatments (SMART-CAT) in first-episode schizophrenia patients: Rationale and trial design (2020) (1)
- Risperidone Nonadherence and Return of Positive Symptoms in the Early Course of Schizophrenia (2012) (1)
- Population pharmacokinetics of antipsychotics (2010) (1)
- CHARACTERISTICS OF HIGH-FUNCTIONING PEOPLE WITH SCHIZOPHRENIA (2008) (1)
- Review for "Monitoring for Myocarditis during Treatment Initiation with Clozapine" (2021) (1)
- Examining racial differences in community integration between black and white homeless veterans (2022) (1)
- 65-80 Risperidone vs. haloperidol in treatment-resistant schizophrenia (1997) (1)
- 77 Long-term Valbenazine Treatment in Patients with Schizophrenia/Schizoaffective Disorder or Mood Disorder and Tardive Dyskinesia (2019) (1)
- Magnetic resonance imaging studies of tardive dyskinesia in schizophrenic patients (1989) (1)
- Low dose pharmacotherapy and skills training (1989) (1)
- Does N-Desmethylolanzapine Increase, or Reduce, the Risk for Antipsychotic-Induced Metabolic Syndrome? (2005) (1)
- 525 Effectiveness of clozapine in treatment resistant schizophrenia (1997) (1)
- Unusual dietary habits in a patient with schizotypal personality disorder (1983) (1)
- Comparative risks of all-cause mortality for Veterans with schizophrenia with ongoing receipt of clozapine and other antipsychotic medications (2022) (1)
- Symptom Rating Scales in Schizophrenia (2012) (1)
- Risks in the Community for Persons With Schizophrenia (2001) (0)
- Why Do Promising Medications Keep Failing in Phase 3 Trials (2017) (0)
- THE EFFICACY OF ARIPIPRAZOLE ON THE FIVE DIMENSIONS OF SCHIZOPHRENIA DERIVED BY FACTOR ANALYSIS: POOLED DATA FROM FIVE SHORT-TERM (2008) (0)
- P.3.c.042 Efficacy of lurasidone in schizophrenia: pooled analysis of the five PANSS factors in short-term trials (2012) (0)
- PMH7 TREATMENT DURATION WITH ORAL AND LONG ACTING INJECTABLE FORMULATIONS OF TYPICAL ANTIPSYCHOTICS IN THE TREATMENT OF SCHIZOPHRENIA RESULTS ACROSS WORLD GEOGRAPHIES (2007) (0)
- Changing the Face of Schizophrenia. (2021) (0)
- Differences in brain activation between control subjects and patients with schizophrenia during mind-wandering: An FMRI study (2003) (0)
- Academic Highlights: New Developments in the Treatment of Schizophrenia. [CME] (2007) (0)
- Neuropsychological components of visual search on the span of apprehension task in schizophrenia (1993) (0)
- Drug treatment in schizophrenia (1993) (0)
- COGNITIVE DYSFUNCTION AND COMMUNITY FUNCTIONING IN SCHIZOPHRENIA: RESULTS FROM THE MATRICS PSYCHOMETRIC AND STANDARDIZATION STUDY (PASS) (2010) (0)
- Integrating psychosocial and pharmacological strategies for maintenance therapy (1995) (0)
- From theWorking Group Conference onMultisite Trial Design for Cognitive Remediation in Schizophrenia (2011) (0)
- Dr. Wirshing and Colleagues Reply (1999) (0)
- Computerized neurocognitive assessment: Clinical trials and FMRI applications (2003) (0)
- P.2.117 The clinical actions of risperidone (1997) (0)
- Application of a single-objective, hybrid genetic algorithm approach to pharmacokinetic model building (2012) (0)
- Patterning Soft Materials { From Methods to Applications Chairs Milan (2001) (0)
- Stigma-Personal Views. (2020) (0)
- Faculty Opinions recommendation of Concurrent and sustained cumulative effects of adolescent marijuana use on subclinical psychotic symptoms. (2016) (0)
- pproaching a Consensus Cognitive Battery for linical Trials in Schizophrenia : The NIMH-MATRICS onference to Select Cognitive Domains and Test riteria (2004) (0)
- Dr. van Kammen and Associates Reply (1983) (0)
- 277 Effects of clozapine and haloperidol on explicit memory in treatment refractory patients (1997) (0)
- The WHO Draft Manual Perpetuates Barriers to Care (2002) (0)
- Meta-analysis of newer antipsychotic drugs (2001) (0)
- Validity and utility of the PANSS negative symptoms factor score as a clinical trial outcome (2014) (0)
- Suicide and Gun Control (2001) (0)
- Subjective response to risperidone and haloperidol: Preliminary results (1996) (0)
- 352. Negative Symptom Trials: Recent Results and Challenges (2017) (0)
- NANOFABRICATION OF SELF-ASSEMBLED MONOLAYERS AND PROTEINS USING SCANNING PROBE LITHOGRAPHY (2001) (0)
- Dr. Marder and Colleagues Reply (1998) (0)
- Smooth, slow release of lithium carbonate for initial or maintenance treatment of mania associated with bipolar disorder (2012) (0)
- Books Received (2007) (0)
- RESULTS OF THE CONSENSUS CONFERENCE ON GUIDELINES FOR NEUROLEPTIC RELAPSE PREVENTION (1992) (0)
- 139 Early Response with Valbenazine and Long-Term Symptom Reduction in Patients with Tardive Dyskinesia: Post Hoc Analysis of the KINECT 3 Study (2020) (0)
- ACADEMIC HIGHLIGHTS (2009) (0)
- 39.4 A DOUBLE-BLIND TRIAL OF VALACYCLOVIR TO IMPROVE COGNITION IN EARLY PHASE SCHIZOPHRENIA: RESULTS FROM THE VISTA STUDY (2018) (0)
- 2010 Wayne Fenton Award for Exceptional Clinical Care The Wayne Fenton Award for Exceptional Clinical Care was established in 2007 to recognize clinical providers who exemplify Dr. Fenton's commitment to improving the daily lives of individuals with schizophrenia. (2010) (0)
- Treatment Responses with Long-Term Valbenazine in Patients with Tardive Dyskinesia (1663) (2020) (0)
- Long-Term Pharmacological Management of Schizophrenia (2014) (0)
- Plasma levels of thiothixene by radioreceptor assay: Clinical usefulness (2004) (0)
- Community Evidence of Clozapine's Effectiveness. (2016) (0)
- Drs. Glick and Marder Reply (2006) (0)
- Family factors identifying schizophrenic patients at risk of relapse (1989) (0)
- Clinical Experiences and Clinical Trials (2013) (0)
- The relationship of serum iron indices to akathisia, tardive dyskinesia, and plasma prolixin levels (1995) (0)
- Psychotic disorders: Many forms, common themes (1996) (0)
- 39.4 EARLY AUDITORY PROCESSING IN SCHIZOPHRENIA: RELATIONSHIPS TO CLINICAL SYMPTOMS AND COGNITIVE REMEDIATION (2019) (0)
- between General Relief and Remission Criteria in the Positive and Negative Syndrome Scale (PANSS): A Post-treatment Bifactor Item Response Theory Model. (2018) (0)
- Pharmacokinetic aspects of neuroleptics and prediction of outcome (1994) (0)
- O12.6. LONG-TERM EFFECTS OF VALBENAZINE ON TARDIVE DYSKINESIA IN PATIENTS WITH SCHIZOPHRENIA/SCHIZOAFFECTIVE DISORDER: RESULTS FROM AN OPEN-LABEL, ROLLOVER STUDY (2019) (0)
- Psychopharmacologic Treatment of Schizophrenia 287 by (2005) (0)
- Pharmacological management of treatment-resistant schizophrenia: fundamentals of clozapine (2018) (0)
- Long-term treatment with valbenazine 40 mg once-daily in adults with Tardive dyskinesia (2020) (0)
- Atypical antipsychotics and cognitive brain activation in schizophrenia (2002) (0)
- Psychosis among individuals with methamphetamine use disorder is associated with elevated rates of hospitalizations and emergency department visits across an academic health care system. (2023) (0)
- Risperidone vs haloperidol on spatial working memory (1995) (0)
- Akathisia with haloperidol and thiothixene. (1984) (0)
- 39 Long-term Safety and Tolerability of Once-Daily Valbenazine in Patients with Tardive Dyskinesia (2019) (0)
- Remote Assessment of Negative Symptoms of Schizophrenia (2023) (0)
- of the steady-state pharmacokinetic profile of decanoate by gas chromatography/mass spectrometry detection (1992) (0)
- Introducing Schizophrenia Bulletin Open (2020) (0)
- New Paradigms for Treatment Development (2008) (0)
- Correction: An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels. (2022) (0)
- Illustrative case studies (2018) (0)
- Novel Treatments of Psychosis (2015) (0)
- The Importance of Adequately Powered Clinical Studies: Response to Khan et al. (2018) (0)
- Optimizing pharmacotherapy of schizophrenia for individuals (2004) (0)
- Onset and Resolution of Key Adverse Events in Valbenazine-Treated Patients with Tardive Dyskinesia: Pooled Analyses from Two Long-Term Clinical Trials. (2021) (0)
- Faculty Opinions recommendation of Endogenous and Antipsychotic-Related Risks for Diabetes Mellitus in Young People With Schizophrenia: A Danish Population-Based Cohort Study. (2017) (0)
- PRACTICE AND LEARNING EFFECTS WITH NEUROPSYCHOLOGICAL BATTERIES IN PATIENTS WITH SCHIZOPHRENIA (2008) (0)
- Protocol : MK-0777 for the Treatment of Cognitive Impairments in Patients with Schizophrenia Treatment Units for Research of Neurocognition in Schizophrenia ( TURNS ) PI : (0)
- Physically Restraining Children at Home or School (2002) (0)
- Schizoaffective Disorder and Drug-Free Improvement-Reply (1981) (0)
- 38 Global Improvement and Patient Satisfaction: Results from a Long-term, Open-label, Rollover Study of Valbenazine in Tardive Dyskinesia (2019) (0)
- 140 Effects of Long-Term Valbenazine on Tardive Dyskinesia in KINECT 4: Post Hoc Response and Shift Analyses (2020) (0)
- SELEGILINE AND AKATHISIA, TARDIVE DYSKINESIA, AND NEGATIVE SCHIZOPHRENIC SYMPTOMS (1992) (0)
- Poster #209 EFFICACY OF LURASIDONE IN SCHIZOPHRENIA: RESULTS OF A FACTOR ANALYSIS OF 5 POOLED SHORT-TERM STUDIES (2012) (0)
- Large Data Sets Can Be Dangerous (2003) (0)
- The Neuroleptic Dysphoria Syndrome (1989) (0)
- 117. Biomarker Assessment of Dose Dependent Target Engagement of mGluR-2,3 Partial Agonist for Schizophrenia Treatment (2019) (0)
- Work Disability After Major Mental Illness and Trauma (2001) (0)
- Faculty Opinions recommendation of A Population-Based Analysis of the Relationship Between Substance Use and Adolescent Cognitive Development. (2019) (0)
- N-Acetylcysteine effects on glutathione and glutamate in schizophrenia: A preliminary MRS study (2022) (0)
- 104. Antipsychotic Drugs (2015) (0)
- The Ethics of Cost Shifting in Community Psychiatry (2002) (0)
- Predictors of Risk of Relapse in Schizophrenia (1991) (0)
- The Wheel, Reinvented (2002) (0)
- Ellen Stover (2014) (0)
- Treatment Research and the Causes of Schizophrenia (1999) (0)
- COURSE OF PSYCHOPATHOLOGY IN SCHIZOPHRENIA (2008) (0)
- Behavioral Toxicity of Antipsychotic Drugs ' l ' heodore (0)
- BRIEF REPORTS The Efficacy of Piquindone, a New Atypical Neuroleptic, in the Treatment of the Positive and Negative Symptoms of Schizophrenia (1987) (0)
- ARIPIPRAZOLE IN COMBINATION WITH RISPERIDONE OR QUETIAPINE: RESULTS FROM A 16-WEEK, RANDOMIZED, DOUBLE-BLIND STUDY IN SUBJECTS WITH SCHIZOPHRENIA (2008) (0)
- S.20.05 NIMH/FDA guidelines for clinical trials for cognition in schizophrenia: how much have we advanced? (2010) (0)
- Adverse Effects of Psychotropic Drugs (1995) (0)
- Rehospitalization rates and antipsychotic medications (2001) (0)
- Schizophrenic patients' perceptions of relatives and contact: One-year outcome (1993) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Stephen R Marder?
Stephen R Marder is affiliated with the following schools:
